Opendata, web and dolomites

MEDMICO

Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEDMICO project word cloud

Explore the words cloud of the MEDMICO project. It provides you a very rough idea of what is the project "MEDMICO" about.

complications    patients    projections    shift    central    evidenced       monitor    date    chemistry    pilot    incorporates    positioning    abnormalities    kidney    trials    forefront    incumbent    innovation    temperature    comorbid    months    validation    clinics    submission    usability    creatinine    population    radisens    panels    efficiencies    renal    patient    outcomes    quad    dublin    disruptive    poct    contractor    biomaterials    single    pipette    mode    medmico    cardiovascular    provides    12    extensive    gt    turbidimetry    accuracy    regulatory    delivering    trl8    clinical    life    diagnostics    room    prototype    counting    disease    rising    healthcare    pharmacies    tests    comorbidity    breakthrough    optimal    combat    shelf    trinity    diabetes    precision    efficient    launch    2035    multiple    hba1c    majority    co    sub    1st    epidemic    lab    outpatient    ischemic    comorbidities    near    care    segments    immunoassays    ready    drive    diabetic    diagnose    screen    2013    away    point    platform    revenues    heart    sensitivity    validated    workflow    diagnostic    spearhead    morbid    college    adult    vitro    storage    cell    expertise    primary    lipids    laboratories    integrating      

Project "MEDMICO" data sheet

The following table provides information about the project.

Coordinator
RADISENS DIAGNOSTICS LIMITED 

Organization address
address: UNITS 1-3 WESTPOINT BUILDINGS LINK ROAD BALLINCOLL
city: CORK
postcode: IP31 HF29
website: www.radisens.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.radisens.com/
 Total cost 4˙487˙525 €
 EC max contribution 4˙487˙525 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RADISENS DIAGNOSTICS LIMITED IE (CORK) coordinator 4˙487˙525.00

Map

 Project objective

Diabetes affects 8.5% (2013) of the adult European population rising to 10.3% (2035) and is associated with co-morbid conditions such as cardiovascular and renal abnormalities. These lead to diabetic complications, ischemic heart disease, heart failure and kidney failure. Management of this growing epidemic requires a shift in care management and delivery, away from lab testing. The majority of current diagnostic testing for diabetes and comorbidities involves central laboratories as incumbent in-vitro diagnostic point-of-care testing (PoCT) provides sub-optimal accuracy and single tests (rather than needed panels) for diabetes and its comorbidities. MEDMICO will spearhead a diagnostic breakthrough by delivering the 1st quad-mode PoCT platform integrating immunoassays, turbidimetry, clinical chemistry and cell counting. HbA1c, Lipids and Creatinine tests will be integrated on to a single diabetes comorbid platform with state-of-the-art sensitivity/precision, room temperature storage, >12 months’ shelf-life and integrated pipette to screen, diagnose and monitor patients, within primary care, outpatient clinics and pharmacies. This will improve patient outcomes and healthcare efficiencies, positioning Europe at the forefront of healthcare innovation and deliver an efficient platform to combat this epidemic. MEDMICO incorporates extensive technical, clinical and exploitation expertise - Radisens’ disruptive PoCT prototype and Trinity College Dublin (sub-contractor) biomaterials expertise and diabetes patient access. MEDMICO’s potential is evidenced by Radisens’ revenues to date and large near-term projections from diagnostics partners before its launch. Existing research of end-user needs and workflow assessment will drive platform development and pilot production, with clinical validation and usability trials in multiple PoCT segments to TRL8. This will deliver a validated quad-mode diabetes comorbidity platform, ready for regulatory submission.

 Deliverables

List of deliverables.
Target stakeholder web site & project presentation Websites, patent fillings, videos etc. 2019-07-24 15:31:59

Take a look to the deliverables list in detail:  detailed list of MEDMICO deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDMICO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDMICO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More